Sugi Predict

Sugi Predict / Compounds / SCHEMBL1065626

SCHEMBL1065626

SCHEMBL1065626

Cc1cn([C@@H]2O[C@H](COP(N)O)[C@@H](O)[C@H]2O)c(=O)nc1N

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.44
▸ MTOR P42345 2/20 0.44
▸ THRB P10828 1/20 0.44
▸ MDM2 Q00987 1/20 0.44
▸ NCOA1 Q15788 1/20 0.44
▸ NCOA3 Q9Y6Q9 1/20 0.44
▸ GMNN O75496 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ DNMT1 P26358 1/20 0.44
▸ THPO P40225 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ BLM P54132 1/20 0.44
▸ HBB P68871 1/20 0.44
▸ PMP22 Q01453 1/20 0.44
▸ P2RY6 Q15077 2/20 0.43
▸ PRMT5 O14744 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24798428 0.92 LMNA (0.45) LMNAMTORTHRBMDM2NCOA1
SCHEMBL1684799 0.87 ADK (0.52) LMNAMTORTHRBMDM2NCOA1
SCHEMBL234387 0.87 LMNA (0.46) LMNAMTORTHRBMDM2NCOA1
SCHEMBL21998920 0.87 ADK (0.52) LMNAMTORTHRBMDM2NCOA1
SCHEMBL29495155 0.87 ADK (0.47) LMNAMTORTHRBMDM2NCOA1
SCHEMBL1065623 0.86 LMNA (0.57) LMNAMTORTHRBMDM2NCOA1
SCHEMBL17748441 0.85 ADORA3 (0.53) LMNAMTORTHRBMDM2NCOA1
SCHEMBL21275623 0.85 LMNA (0.50) LMNAMTORTHRBMDM2NCOA1
SCHEMBL16629487 0.85 LMNA (0.50) LMNAMTORTHRBMDM2NCOA1
SCHEMBL5697581 0.83 LMNA (0.62) LMNAMTORTHRBMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250250565-A1 OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES ALPHA ANOMERIC SAS (FR) 2025-08-07 — — US disclosed
US-20240343752-A1 NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM UNIV BERN (CH) 2024-10-17 — — US disclosed
US-11919922-B2 Bicyclic nucleosides and oligomers prepared therefrom UNIVERSITAT BERN (CH) 2024-03-05 — — US disclosed
CN-110023322-B Novel bicyclic nucleosides and oligomers prepared therefrom 伯尔尼大学 2023-10-27 — — CN disclosed
US-20230132377-A9 OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES ALPHA ANOMERIC SAS (FR) 2023-04-27 — — US disclosed
US-20220089632-A1 NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM UNIV BERN (CH) 2022-03-24 — — US disclosed
US-20220017898-A1 OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES ALPHA ANOMERIC SAS (FR) 2022-01-20 — — US disclosed
US-11028117-B2 Bicyclic nucleosides and oligomers prepared therefrom Universität Bern (CH) 2021-06-08 — — US disclosed
EP-3790968-A1 OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES Alpha Anomeric SAS (FR) 2021-03-17 — — EP disclosed
CN-112424352-A Oligonucleotide conjugates comprising 7 '-5' -alpha-anomeric bicyclic sugar nucleosides 阿尔法阿诺麦里克公司 2021-02-26 — — CN disclosed
US-20010006801-A1 BASE-MODIFIED ENZYMATIC NUCLEIC ACID USMAN NASSIM (US) 2001-07-05 — — US disclosed
US-5891684-A RIBOZYMES RIBOZYME PHARMACEUTICALS, INC. (US) 1999-04-06 — — US disclosed
US-5879938-A RIBOZYME WITH INCREASED ACTIVITY BY SUBSTITUTION OF MODIFIED NUCLEOTIDE INTO SUBSTRATE BINDING ARM OR CATALYTIC CORE RIBOZYME PHARMACEUTICALS, INC. (US) 1999-03-09 — — US disclosed
US-5767263-A Base-modified enzymatic nucleic acid RIBOZYME PHARMACEUTICALS, INC. (US) 1998-06-16 — — US disclosed
EP-0799313-A2 METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES RIBOZYME PHARMACEUTICALS, INC. (US) 1997-10-08 — — EP disclosed
US-5672501-A Base-modified enzymatic nucleic acid RIBOZYME PHARMACEUTICALS, INC. (US) 1997-09-30 — — US disclosed
US-5672511-A Base-modified enzymatic nucleic acid RIBOZYME PHARMACEUTICALS, INC. (US) 1997-09-30 — — US disclosed
EP-0728204-A1 BASE-MODIFIED ENZYMATIC NUCLEIC ACID RIBOZYME PHARMACEUTICALS, INC. (US) 1996-08-28 — — EP disclosed
WO-1996018736-A2 METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES RIBOZYME PHARMACEUTICALS, INC. (US) 1996-06-20 — — WO disclosed
WO-1995013378-A1 BASE-MODIFIED ENZYMATIC NUCLEIC ACID RIBOZYME PHARMACEUTICALS, INC. (US) 1995-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089632-A1 NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM RRM2, PRPF31, PYGM LMNA 309/4885MTOR 1634/4885THRB 3123/4885
US-11028117-B2 Bicyclic nucleosides and oligomers prepared therefrom RRM2, NUDT1, REV1 LMNA 275/4885MTOR 1438/4885THRB 2711/4885
US-20240343752-A1 NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM RRM2, RRM2B, REV1 LMNA 305/4885MTOR 2034/4885THRB 3357/4885
US-11919922-B2 Bicyclic nucleosides and oligomers prepared therefrom RRM2, REV1, NUDT1 LMNA 268/4885MTOR 1647/4885THRB 2870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.